Artiva insider plans $262K Rule 144 stock sale

A holder associated with Artiva Biotherapeutics has filed to sell 23,429 Rule 144 shares after prior sales of 61,888 shares in the past three months.

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. (ARTV) received a notice that Fred Aslan intends to sell 23,429 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC, with a stated aggregate market value of $262,170.51 as of September 8, 2026. The shares derive from restricted stock units that vested between May 15, 2025 and September 1, 2026. Over the prior three months, the same person reported selling 61,888 shares of Artiva common stock for $690,391.58.

Key Figures

Proposed shares to be sold under Rule 144: 23,429 shares Aggregate market value of proposed sale: $262,170.51 Shares sold in prior 3 months: 61,888 shares +3 more

6 metrics

Proposed shares to be sold under Rule 144 23,429 shares Common stock for the account of Fred Aslan

Aggregate market value of proposed sale $262,170.51 Market value associated with 23,429 shares as of September 8, 2026

Shares sold in prior 3 months 61,888 shares Common stock sale on September 3, 2026

Proceeds from prior 3-month sale $690,391.58 Sale of 61,888 shares on September 3, 2026

RSU vesting period May 15, 2025 to September 1, 2026 Period during which RSUs vested and yielded the shares to be sold

Date of Rule 144 notice September 8, 2026 Date of notice for proposed Rule 144 sale

Key Terms

Rule 144, Restricted Stock Units, aggregate market value, common stock, +1 more

5 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Units financial

"The securities to be sold were acquired upon the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

aggregate market value financial

"Common ... 23429 | 262170.51 | 48890121 | 09/08/2026"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

common stock financial

"Common | Morgan Stanley Smith Barney LLC Executive Financial Services"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Securities To Be Sold regulatory

"144: Securities To Be Sold Common | 05/15/2025 | Restricted Stock Units"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing mean for Artiva Biotherapeutics (ARTV)?

The filing states that 23,429 shares of Artiva common stock may be sold under Rule 144 for the account of Fred Aslan. It is a notice of a proposed resale of restricted or control securities, not an issuance of new shares by Artiva.

How many ARTV shares is Fred Aslan planning to sell under this Form 144?

The notice covers a proposed sale of 23,429 shares of Artiva common stock. The filing lists an aggregate market value of $262,170.51 tied to this amount as of September 8, 2026.

What prior Artiva (ARTV) share sales by Fred Aslan are disclosed?

The document reports that on September 3, 2026, 61,888 shares of Artiva common stock were sold for $690,391.58. These are sales during the three months preceding the new proposed Rule 144 sale.

How were the Artiva (ARTV) shares in this Form 144 acquired?

The filing explains that the securities to be sold were acquired upon the vesting of restricted stock units during the period from May 15, 2025 through September 1, 2026. The issuer is listed as Artiva Biotherapeutics, Inc..

Who is the broker handling the proposed ARTV share sale under Rule 144?

The proposed sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza in New York. The securities listed are common stock of Artiva Biotherapeutics, Inc.

On which market is the Artiva Biotherapeutics (ARTV) stock in this filing listed?

The Form 144 identifies the market for the common stock as NASDAQ. The proposed sale of 23,429 shares of Artiva common stock is referenced with this market designation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 04:32 PM EDT Accepted by SEC EDGAR 09/08/2026 - 04:31 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001909362
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Artiva Biotherapeutics, Inc.
SEC File Number	001-42179
Address of Issuer	5505 Morehouse Drive, Suite 100 San Diego CALIFORNIA 92121
Phone	8582674467
Name of Person for Whose Account the Securities are To Be Sold	FRED ASLAN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	23429	262170.51	48890121	09/08/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/15/2025	Restricted Stock Units	Issuer			23429	05/15/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
FRED ASLAN 5505 Morehouse Drive, Suite 100 San Diego CA 92121	Common	09/03/2026	61888	690391.58

144: Remarks and Signature

Remarks	The securities to be sold were acquired upon the vesting of restricted stock units during the period of 05/15/2025 through 9/1/2026
Date of Notice	09/08/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Fred Aslan
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)